Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 7/20 | 0.45 |
| ▸ | LMNA | P02545 | 4/20 | 0.45 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.41 |
| ▸ | PPARG | P37231 | 4/20 | 0.39 |
| ▸ | PPARA | Q07869 | 4/20 | 0.39 |
| ▸ | PTPRF | P10586 | 1/20 | 0.39 |
| ▸ | PTPRA | P18433 | 1/20 | 0.39 |
| ▸ | PTPN7 | P35236 | 1/20 | 0.39 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11993095 | 0.91 | LMNA (0.47) | PTPN1LMNAPTGER4NPSR1RXFP1 | |
| SCHEMBL6904181 | 0.87 | PTPN1 (0.38) | PTPN1LMNAPTGER4NPSR1RXFP1 | |
| SCHEMBL3976050 | 0.85 | LMNA (0.46) | PTPN1LMNAPTGER4NPSR1RXFP1 | |
| SCHEMBL3979354 | 0.80 | PPARG (0.46) | LMNAPPARGPPARA | |
| SCHEMBL3972905 | 0.79 | PPARG (0.54) | PPARGPPARA | |
| SCHEMBL3972070 | 0.79 | PPARG (0.45) | PTPN1LMNAPPARGPPARAMAPT | |
| SCHEMBL3968405 | 0.76 | PPARG (0.48) | PTPN1LMNAPPARGPPARA | |
| SCHEMBL13418750 | 0.75 | PTPN1 (0.63) | PTPN1LMNAPTGER4PPARGPPARA | |
| SCHEMBL3978556 | 0.75 | PPARG (0.53) | LMNANPSR1PPARGPPARAALDH1A1 | |
| SCHEMBL3976053 | 0.73 | LMNA (0.48) | LMNAPTGER4NPSR1RXFP1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7491747-B2 | 4-(Arylthio)- or (4-heteroarylthio)butyric acid derivatives that may be used in the treatment of dyslipidaemia, atherosclerosis and diabetes | MERCK PATENT GMBH (DE) | 2009-02-17 | — | — | US | disclosed |
| US-20050020651-A1 | Butyric acid derivatives | MERCK PATENT GMBH (DE) | 2005-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050020651-A1 | Butyric acid derivatives | GPR119, DBI, GABRB1 | PTPN1 2689/4885LMNA 743/4885PTGER4 2216/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.